Roth Capital Comments on ZYUS Life Sciences Corporation’s FY2023 Earnings (CVE:ZYU)

ZYUS Life Sciences Corporation (CVE:ZYUFree Report) – Analysts at Roth Capital issued their FY2023 earnings per share (EPS) estimates for ZYUS Life Sciences in a research report issued to clients and investors on Thursday, March 14th. Roth Capital analyst S. Fortune forecasts that the company will post earnings per share of ($0.52) for the year. Roth Capital has a “Buy” rating on the stock. Roth Capital also issued estimates for ZYUS Life Sciences’ Q4 2023 earnings at ($0.06) EPS, Q1 2024 earnings at ($0.07) EPS, Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.28) EPS.

Separately, Stifel Canada restated a “speculative buy” rating on shares of ZYUS Life Sciences in a research report on Friday, January 26th.

Check Out Our Latest Analysis on ZYU

ZYUS Life Sciences Stock Performance

Read More

Receive News & Ratings for ZYUS Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZYUS Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.